Skye Bioscience Names Paul Grayson as Chairman

MT Newswires Live10-29

Skye Bioscience (SKYE) said Tuesday that it has appointed independent director Paul Grayson as its new chairman effective Oct. 25.

Grayson succeeds Punit Dhillon, who will remain as Skye's chief executive officer and as a board member, the company added. Grayson currently serves as chief executive officer of Radionetics Oncology.

Skye Bioscience shares were down more than 3% in Tuesday trading.

Price: 4.97, Change: -0.19, Percent Change: -3.59

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment